| Ytd | -36.54% | |
| 1y | -32.91% |
| Open | 7.32 | Prev Close | 7.32 | Low | 7.26 | High | 7.46 | Mkt Cap | 575.23M |
| Vol | 1.19M | Avg Vol | 1.06M | EPS | 2.05 | P/E | 3.60 | Forward P/E | 17.54 |
| Beta | 1.58 | Short Ratio | 5.12 | Inst. Own | 31.92% | Dividend | N/A | Div Yield | N/A |
| Ex Div Date | N/A | Earning | 11-16 | 50-d Avg | 7.84 | 200-d Avg | 7.92 | 1yr Est | 16.25 |
CRMD News
Investors with an interest in Medical - Biomedical and Genetics stocks have likely encountered both
Oppenheimer analyst Les Sulewski initiates coverage on Cormedix (NASDAQ:CRMD) with a Outperform r
The consensus price target hints at a 67.7% upside potential for CorMedix (CRMD). While empirical re
PARSIPPANY, N.J., Sept. 01, 2026 (GLOBE NEWSWIRE) -- CorMedix Therapeutics (Nasdaq: CRMD), a biophar
CorMedix (CRMD) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the co
The consensus price target hints at a 66% upside potential for CorMedix (CRMD). While empirical rese
RBC Capital analyst Leonid Timashev maintains Cormedix (NASDAQ:CRMD) with a Outperform and raises
CorMedix stock rises 15% after Q2 earnings and revenues beat estimates, driven by solid DefenCath ut
CorMedix Inc. (CRMD) Q2 2026 Earnings Call Transcript
CorMedix NASDAQ: CRMD reported second-quarter 2026 consolidated revenue of $101.9 million and adjust
CorMedix Inc. (NASDAQ:CRMD) shares are rising on Thursday after the company reported strong second-q
CorMedix Q2 earnings beat estimates as sales more than doubled, DefenCath revenue grew, and the comp
Nasdaq Composite gained 200 points on Thursday, while Accelerant Holdings (NYSE: ARX) rose 44.2% af
CorMedix (CRMD) came out with quarterly earnings of $0.29 per share, beating the Zacks Consensus Est
On Thursday, Cormedix (NASDAQ:CRMD) discussed second-quarter financial results during its earnings c
Cormedix (NASDAQ:CRMD) affirms FY2026 sales outlook from $325.000 million-$345.000 million to $325.0
‒ Q2 2026 Consolidated Revenue of $101.9 million ‒ ‒ Q2 2026 Net Income of $26.0 million ; Adjusted
PARSIPPANY, N.J., July 29, 2026 (GLOBE NEWSWIRE) -- CorMedix Therapeutics (Nasdaq: CRMD) today annou
US stock futures mixed, Dow futures up 0.2%. Frequency Electronics (FEIM) shares down 8.3% after rep
RBC Capital analyst Leonid Timashev maintains Cormedix (NASDAQ:CRMD) with a Outperform and lowers
US stock futures lower as Dow falls 100 points. Nike shares down 4% after Q4 results. Shutterstock,
CorMedix posted surging DefenCath-led revenue and stronger profitability, but reimbursement changes
CorMedix broadens beyond DefenCath with Melinta assets, Rezzayo potential and cost synergies as reim
CorMedix is shifting from a single-product launch story as DefenCath drives revenue and Rezzayo adds
The Federal Circuit's decision on Friday upheld the district court's findings that Nexus'
PARSIPPANY, N.J., June 08, 2026 (GLOBE NEWSWIRE) -- CorMedix Therapeutics (Nasdaq: CRMD) today annou
CorMedix is rated a 'Strong Buy' below ~$8.35, with ~114% upside to a $17.5 fair value based on DCF
CorMedix NASDAQ: CRMD CEO Joe said the company is preparing for several potential commercial and reg
CorMedix beats Q1 estimates as DefenCath demand surges and raises 2026 guidance on stronger executio
PARSIPPANY, N.J., May 15, 2026 (GLOBE NEWSWIRE) -- CorMedix Therapeutics (Nasdaq: CRMD) today announ
CorMedix raises 2026 guidance after Q1 revenue surges on strong DefenCath demand and higher profitab
Cormedix (NASDAQ:CRMD) raises FY2026 sales outlook from $300.000 million-$320.000 million to $325.00
Cormedix (NASDAQ:CRMD) reported quarterly earnings of $0.43 per share which beat the analyst consens
Here's a look at this week's earnings reports that are most likely to be watched by retail i
Hedge fund Elliott Management revealed a Q2 portfolio reshuffle, adding new positions tied to major
Performance Food rejects offer; Lufthansa drops Air Europa bid; NFL inks deal with ESPN; Claire'
